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1. Introduction 
The ‘minor hemoglobins’ (Hb AI,- ,.) were the first 
examples to show that glucose can react non-enzy- 
matically with proteins in the human body to form 
stable glycosyl-protein adducts. Other proteins have 
been observed to undergo non-enzymatic glycosyla- 
tion, such as the eye lens crystallins [I], red cell 
membrane proteins [2,3], serum albumin [4-61. The 
amount of HbA,,-, is increased in diabetic patients 
depending on the level of,hyperglycemia; this holds 
also for glycosylated albumin [7,8], and erythrocyte 
membrane proteins [2,3]. Apart from the diagnostic 
value of HbAr and glycosyl-albumin as tools for 
long-term control of diabetes, protein glycosylation 
has attracted special interest with regard to the role it 
may play in the development of the late complica- 
tions of diabetes. In these studies we have found that 
glucose is covalently bound to e-amino groups of 
lysine of human apo-lipoproteins upon incubation, 
in vitro. Moreover, we could show that the level of 
glycosylated apoprotein B (apo-B) of the low density 
lipoproteins (LDL) is increased in the serum from 
diabetic patients. 
2. Materials and methods 
Human serum albumin and reagents for the 
quantitative determination of apo-A and apo-B by 
immunodiffusion were from Behringwerke (Marburg). 
Immobilised heparin (lipotype) was purchased from 
Dedicated to Professor Helmuth Holzer on the occasionof his 
60th birthday 
Elsevier/North-Holland Biomedical Press 
Panchem (Kleinwallstadt). Chemicals used for poly- 
acrylamide gel electrophoresis were from Serva 
(Heidelberg), all other chemicals were from Merck 
(Darmstadt). HPLC analysis was done on a Waters 
apparatus (Milford USA). D-[U-r4C]Glucose was 
from Radiochemical Centre (Braunschweig). To 
remove any radioactive contaminants which are 
prone to react rapidly with albumin (unpublished) 
and could invalidate the in vitro labelling experiments 
[9], the preparation was pre-purified by dissolving 
6.9 pmol D- [U-‘“Cl glucose in 1 ml phosphate-buffered 
saline (PBS) containing 2 mg human serum albumin. 
After 36 h incubation at 37°C the albumin was pre- 
cipitated by acetone, the supernatant evaporated, and 
the glucose purified by gel-filtration on Sephadex 
G-25. 
2.1. Purification of lipoproteins 
Human serum lipoproteins for incubation studies 
were purified by ultracentrifugation essentially 
according to [lo]. APO-A and B content was estimated 
by radial immunodiffusion. LDL from normal and 
diabetic patients were isolated as follows: 0.5 ml 
serum was applied to a heparin column (Panchem) 
and the &lipoproteins were eluted according to the 
supplier’s instructions. After adjusting the density to 
1.065 by extensive dialysis the /3-lipoproteins were 
flotated by ultracentrifugation at 15°C for 18 h at 
150 000 X g. LDL and VLDL were separated under 
the same conditions at a density of 1.006. LDL was 
precipitated and delipidated according to [ 111. 
LDL from patients was also purified by immuno- 
adsorption [ 121 on a column containing Sepharose- 
bound anti-apoprotein B immunoglobulin. The 
immobilized anti-apoprotein B was kindly provided 
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by Professor W. Stoffel (Koln). Serum samples of 
1 ml were applied and recycled 5 times for complete 
absorption. After washing with PBS, the apo-B con- 
taining lipoproteins were eluted with 0.2 M glycine- 
HCl buffer (pH 2.8). VLDL was separated by ultra- 
centrifugation and LDL was flotated at a density of 
1.06. 
2.2. Determination of protein (lysinej-bound glucose 
Protein bound glucose was determined as in [ 131. 
The method is based on the formation of furosine 
(e-N-(2-furoylmethyl)L-lysine) upon hydrolysis of 
the proteins in 6 N HCl which is separated on HPLC 
and quantified by its UV absorbance against a syn- 
thetic fructose-lysine standard. As a control, protein 
samples were treated prior to hydrolysis at pH 7.8 
with -10 mg NaB& for 60 min at room temperature 
to reduce the ketoamine linkages, and dialyzed against 
PBS. After reduction no furosine peak was detectable. 
2.3. SDS-polyacrylamide gel electrophoresis 
Electrophoresis was done on 10% polyacrylamide 
gels containing 0.1% SDS as in [ 141. Lipoproteins 
were dissolved in 100 j,d 0.2% SDS containing 3 mM 
Tris-HCl buffer (pH 8.2) and 125 mM P-mercapto- 
ethanol to reduce SH-bonds by heating to 95°C for 
5 mm followed by 1 h at 37°C. Prior to application 
of protein the gels were subjected to pre-electropho- 
resis for -2 h The proteins were separated at 2.5 mA/ 
gel for 1.5 h and stained overnight with Coomassie 
brilliant blue. 
3. Results 
3.1. In vitro incorporation ofglucoseinto lipoproteins 
Purified LDL and HDL from normal human serum 
incorporated glucose via e-aminolysine groups in a 
time-dependent manner when incubated in vitro in a 
high glucose medium. This is illustrated in fig.1 which 
further indicates that most of the r4C-radioactivity 
taken up is recovered by furosine analysis as lysine- 
bound glucose. The small remaining part may be 
attributable to other ketoamine linkages, e.g., of the 
N-terminal amino acids. As can also be seen in fig.1 
small amounts of protein bound glucose were already 
present in the native lipoproteins, i.e., at zero time 
of incubation. 
The dependence of lipoprotein glycosylation on 
the glucose concentration of the medium displayed 
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also a linear relationship over a 1 O-fold range up to 
55 mmol/l glucose (fig.2). These studies further 
indicate that the incorporation of glucose into LDL 
and HDL is by -25% lower compared with human 
serum albumin. Further proof for covalent incorpora- 
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Fig.1. Time dependent incorporation of [U-r4C]glucose into 
HDL- and LDL-protein. HDL and LDL with a protein 
content of 2.55 mg ape-A and 2.45 mg apo-B, respectively 
were incubated at 37’C in 5 ml PBS (pH 7.4) containing 
27.5 mmol [U-“C]glucose/l with a specific radioactivity of 
9.13 X lo5 dpm/pmol, and 0.02% NaN,. At the times indi- 
cated 1 ml samples were withdrawn, dialyzed against isotonic 
NaCl solution, and the protein precipitated and delipidated 
by acetone as in section 2. The precipitate was taken up in 
6 N HCl, hydrolyzed and analyzed for furosine content as in 
[ 131. A sample of the hydrolysate was taken for measure- 
ment of radioactivity using a Packard Liquid scintillation 
counter. Data calculated from radioactivity (0) or from furo- 
sine (0). 
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Fig.2. Concentration dependent incorporation of glucose into 
human serum albumin (e), LDL (n), and HDL (A). Incuba- 
tion was performed for 8 days at 37°C in 0.4 ml PBS (pH 7.4) 
containing 0.02% NaN, and increasing concentrations of glu- 
cose asgiven on the abscissa. Protein was 1 mg/ml. For further 
treatment see fig.1. 
tion of [“Qglucose into the protein moiety of the 
lipoprotein fractions was obtained by studying the 
distribution of radioactivity of the protein bands 
after SDS-polyacrylamide gel electrophoresis. As 
shown in fig.3(a,b) the bulk of radioactivity of LDL 
and VLDL, respectively, coincided with the fractions 
corresponding to apo-B. Small amounts of label 
appeared at the position of apo-E, and also in the 
apo-C region of VLDL. The VLDLfraction also con- 
tained some albumin as indicated in fig.3(b). Fig3(c) 
shows the results of the corresponding experiments 
with HDL. The radioactive label, comigrates with the 
apoproteins Ai and A,, respectively. Both apopro- 
teins seem to be glycosylated at about the same rate. 
3.2. Increase of glycosylated LDL in diabetes 
In order to establish if lipoprotein glycosylation is 
enhanced also in vivo at increased glucose concentra- 
tions we have examined the LDL fractions obtained 
from serum of diabetic patients. From the data in 
fig.4 it is clear that the LDL apo-B of diabetics con- 
tains a higher proportion of lysine bound glucose 
when compared with non-diabetic persons. Based on 
an apo-B Mr = 255 000 [ 151 normal apo-B is calcu- 
lated to contain -0.5 mol glucose/mol protein while 
in the diabetic with the highest level of glycosylated 
LDL this ratio was increased to 1.9. 
Fig.3. Analysis of [Wlglucose-treated lipoproteins by SDS- 
polyacrylamide gel electrophoresis. VLDL (0.86 mg protein/ 
ml), LDL (0.38 mg protein/ml), and HDL (1.76 mg/ml) 
were incubated at 3?C in PBS containing 31.1,48.4 and 
27.5 mmol [U-‘4C]glucose/l (spec. radioact. 8-10 X 10‘ 
dpm) for 8 days (VLDL 13 days). After dialysis, acetone 
precipitation and delipidation the proteins were treated for 
electrophoresis as in section 2.3. (a) LDL; (b) VLDL; (c) 
HDL. LDL and HDL were kindly provided by Dr Miinscher, 
Behringwerke (Marburg). A,, A,, B, C, E indicate the position 
of the corresponding apoproteins, Alb = albumin. 
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Fig.4. Glycosyl-LDL levels in non-diabetics (0) and diabetic 
patients (0). For methodological and analytical details see 
section 2. 
4. Discussion 
‘Ihe discovery of a specific LDL-receptor path- 
way and its defect in familial hypercholesterolemia 
has provided new insight into the regulation of cho- 
lesterol metabolism and its inter-relationships with 
the development of atherogenesis [ 161. The binding 
of lipoproteins to their receptors is determined by the 
protein moieties and can be changed by selective 
chemical modification of lysine or arginine residues 
of the apoproteins [ 171. Of particular interest in 
these findings is that chemical modification of lysine 
residues of apo-B by acetylation [ 181 or malondi- 
aldehyde treatment [ 191 results in an increased cellu- 
lar LDLuptake and cholesterol accumulation via 
receptors (scavenger receptors) different from the 
specific receptors for native LDL. The observation 
on LDLglycosylation described here is the first 
example to show that covalent modification of lysine 
groups of apo-B can take place in vivo. If this would 
also challenge the normal celhrlar LDL-receptor 
interactions, the increased level of glycosylated LDL 
in diabetic patients might help to a better under- 
standing of the high incidence of vascular complica- 
tions in diabetes. Cell culture studies on the properties 
of glycosylated lipoproteins are now under way. 
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